Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | TPMT | P51580 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10984138 | 0.98 | AR (0.49) | ARALDH1A1KDM4EHPGDLCK | |
| SCHEMBL3996717 | 0.87 | CFD (0.51) | ARALDH1A1KDM4EHPGDLCK | |
| SCHEMBL1614434 | 0.86 | ALDH1A1 (0.57) | ARALDH1A1KDM4EHPGDLCK | |
| SCHEMBL20855586 | 0.86 | AR (0.50) | ARALDH1A1KDM4EMAPTCA9 | |
| SCHEMBL30468153 | 0.86 | AR (0.50) | ARALDH1A1KDM4EMAPTCA9 | |
| SCHEMBL29546482 | 0.85 | AR (0.49) | ARALDH1A1KDM4EHPGDMAPT | |
| SCHEMBL477893 | 0.85 | AR (0.49) | ARALDH1A1MAPTKMT2AMRGPRX4 | |
| SCHEMBL385459 | 0.85 | AR (0.49) | ARALDH1A1KDM4EHPGDMAPT | |
| SCHEMBL26388273 | 0.84 | GSK3B (0.50) | ARALDH1A1MAPTKMT2AL3MBTL1 | |
| SCHEMBL16955916 | 0.82 | AR (0.53) | ARALDH1A1KDM4EMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492166-B2 | Sulfonylurea derivative and medical uses thereof | SHANGHAI SENHUI MEDICINE CO., LTD (CN) | 2025-12-09 | — | — | US | disclosed |
| CN-120004770-A | Sulfonylurea derivative and medical application thereof | 上海森辉医药有限公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-115836050-B | Sulfonylurea derivative and medical application thereof | 上海森辉医药有限公司 | 2024-12-20 | — | — | CN | disclosed |
| US-20230348371-A1 | SULFONYLUREA DERIVATIVE AND MEDICAL USES THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230348371-A1 | SULFONYLUREA DERIVATIVE AND MEDICAL USES THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230348371-A1 | SULFONYLUREA DERIVATIVE AND MEDICAL USES THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| CN-116444404-A | Salt of sulfonylurea derivative and crystal form thereof | 江苏恒瑞医药股份有限公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-116444403-A | Crystal form of sulfonylurea derivative | 江苏恒瑞医药股份有限公司 | 2023-07-18 | — | — | CN | disclosed |
| WO-2023098876-A1 | CARBONYL SUBSTITUTED DIAZASPIRO COMPOUNDS AND ITS USE | BIONOVA PHARMACEUTICALS (SHANGHAI) LIMITED (CN) | 2023-06-08 | — | — | WO | disclosed |
| EP-4183774-A1 | SULFONYLUREA DERIVATIVE AND MEDICAL USES THEREOF | Shanghai Senhui Medicine Co., Ltd. (CN) | 2023-05-24 | — | — | EP | disclosed |
| WO-2002068417-A2 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| EP-0874843-B1 | SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL) 1,4]DIAZEPANES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | AVENTIS PHARMA INC (US) | 2002-08-07 | — | — | EP | disclosed |
| US-6423704-B2 | CROHN'S DISEAS, ANTIULCER AGENTS, ASTHMA, EMESIS | AVENTIS PHARMACEUTICALS INC. | 2002-07-23 | — | — | US | disclosed |
| US-20010034343-A1 | Novel substituted 4-(1H-benzimidazol-2-yl) [1,4]diazepanes useful for the treatment of allergic diseases | AVENTIS PHARMACEUTICALS INC. | 2001-10-25 | — | — | US | disclosed |
| US-6211199-B1 | HISTAMINE AND TACHYKININ RECEPTOR ANTAGONISTS; ANTIASTHMATICS, ANTIEMETICS; RESPIRATORY SYSTEM DISORDERS, INFLAMMATORY BOWEL DISEASE, CONJUNCTIVITIS | AVENTIS PHARMACEUTICALS INC. | 2001-04-03 | — | — | US | disclosed |
| US-6194406-B1 | HISTAMINE RECEPTOR ANTAGONISTS; TACHYKININ RECEPTOR ANTAGONISTS; ASTHMA; BRONCHITIS; INFLAMMATORY BOWEL DISEASES, INCLUDING CROHN'S DISEASE AND ULCERATIVE COLITIS; SEASONAL RHINITIS; SINUSITIS; ANTIALLERGENS; EMETIC AGENTS | AVENTIS PHARMACEUTICALS INC. | 2001-02-27 | — | — | US | disclosed |
| EP-0920425-A1 | SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL-AMINO)PIPERIDINES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | HOECHST MARION ROUSSEL, INC. (US) | 1999-06-09 | — | — | EP | disclosed |
| EP-0874843-A1 | NOVEL SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL) 1,4]DIAZEPANES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | HOECHST MARION ROUSSEL, INC. (US) | 1998-11-04 | — | — | EP | disclosed |
| WO-1997022604-A1 | NOVEL SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL)[1,4]DIAZEPANES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | HOECHST MARION ROUSSEL, INC. (US) | 1997-06-26 | — | — | WO | disclosed |
| WO-1997019074-A1 | SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL-AMINO)PIPERIDINES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | HOECHST MARION ROUSSEL, INC. (US) | 1997-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034343-A1 | Novel substituted 4-(1H-benzimidazol-2-yl) [1,4]diazepanes useful for the treatment of allergic diseases | HRH4, HRH2, HRH1 | AR 1523/4885ALDH1A1 953/4885KDM4E 1512/4885 |
| US-12492166-B2 | Sulfonylurea derivative and medical uses thereof | PYGB, ATP6V1B2, GLP1R | AR 4744/4885ALDH1A1 802/4885KDM4E 2974/4885 |
| US-20230348371-A1 | SULFONYLUREA DERIVATIVE AND MEDICAL USES THEREOF | PYGB, ATP6V1B2, GLP1R | AR 4744/4885ALDH1A1 802/4885KDM4E 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.